Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Imatinib Mesylate/therapeutic use"'
Autor:
Fanny Delehaye, Jérémie Rouger, David Brossier, Meinolf Suttorp, Adalet Meral Güneş, Petr Sedlacek, Birgitta Versluys, Chi Kong Li, Krzysztof Kalwak, Birgitte Lausen, Culic Srdjana, Michael Dworzak, Andrea Hraskova, Barbara De Moerloose, Farah Roula, Anaïs Briant, Jean-Jacques Parienti, Frédéric Millot
Publikováno v:
Annals of Hematology. 102:563-570
The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984119ca7072821a962c35d827f6af22
https://doi.org/10.1007/s00277-022-05024-1
https://doi.org/10.1007/s00277-022-05024-1
Autor:
Ivo P E Tielbeek, Richard Honeywell, Bram Grob, Pierre M Bet, Harm Jan Bogaard, Monia Guidi, Erik Duijvelaar, Imke H Bartelink, Eleonora L Swart, Nicolas Widmer, Laurent A. Decosterd, Jurjan Aman, Amanda Evelo, Sue D Snape, Henrike Hamer
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT, vol. 10, no. 12, pp. 1497-1511
Bartelink, I H, Bet, P M, Widmer, N, Guidi, M, Duijvelaar, E, Grob, B, Honeywell, R, Evelo, A, Tielbeek, I P E, Snape, S D, Hamer, H, Decosterd, L A, Bogaard, H J, Aman, J & Swart, E L 2021, ' Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials : lessons from the CounterCovid-imatinib-study ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 12, pp. 1497-1511 . https://doi.org/10.1002/psp4.12718
CPT: Pharmacometrics and Systems Pharmacology, 10(12), 1497-1511. Wiley-Blackwell
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)
CPT, vol. 10, no. 12, pp. 1497-1511
Bartelink, I H, Bet, P M, Widmer, N, Guidi, M, Duijvelaar, E, Grob, B, Honeywell, R, Evelo, A, Tielbeek, I P E, Snape, S D, Hamer, H, Decosterd, L A, Bogaard, H J, Aman, J & Swart, E L 2021, ' Elevated acute phase proteins affect pharmacokinetics in COVID-19 trials : lessons from the CounterCovid-imatinib-study ', CPT: Pharmacometrics and Systems Pharmacology, vol. 10, no. 12, pp. 1497-1511 . https://doi.org/10.1002/psp4.12718
CPT: Pharmacometrics and Systems Pharmacology, 10(12), 1497-1511. Wiley-Blackwell
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 12, Pp 1497-1511 (2021)
This study aimed to determine whether published pharmacokinetic (PK) models can adequately predict the PK profile of imatinib in a new indication, such as coronavirus disease 2019 (COVID-19). Total (bound + unbound) and unbound imatinib plasma concen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56b0113a10ff46f52c554a392c3057f2
https://doi.org/10.1002/psp4.12718
https://doi.org/10.1002/psp4.12718
Autor:
Maria A. Pantaleo, Michael C. Heinrich, Antoine Italiano, Claudia Valverde, Patrick Schöffski, Giovanni Grignani, Anna K. L. Reyners, Sebastian Bauer, Peter Reichardt, Daniel Stark, Ghimja Berhanu, Ulrike Brandt, Tommaso Stefanelli, Hans Gelderblom
Publikováno v:
BMC Cancer, 22(1). BMC
BMC Cancer, 22:511. BMC
Scientia
BMC Cancer, 22:511. BMC
Scientia
Background Acquired resistance to approved tyrosine kinase inhibitors limits their clinical use in patients with gastrointestinal stromal tumor (GIST). This study investigated the safety, tolerability and efficacy of alpelisib, a phosphatidylinositol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690d38d90bc8d9c40e2ca50f51ec406f
http://hdl.handle.net/1887/3563459
http://hdl.handle.net/1887/3563459
Autor:
Renaud Du Pasquier, Jean-Philippe Brouland, Denis Comte, Vincent Dunet, Patrizia Comoli, Olivier Spertini, Yordanka Tirefort, Sabine Blum, Françoise Livio, Onya Opota, Yves Chalandon
Publikováno v:
Leukemia and Lymphoma, Vol. 61, No 9 (2020) pp. 2226-2229
Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating, mostly lethal complication due to an opportunistic infection of the central nervous system (CNS) by John Cunningham polyo...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35b1038c760122098cf969063036336c
https://pubmed.ncbi.nlm.nih.gov/32364409
https://pubmed.ncbi.nlm.nih.gov/32364409
Autor:
Inga Mandac Rogulj, Vilim Molnar, Dragan Primorac, Alen Juginović, Luka Boban, Borna Arsov, Vid Matišić
Publikováno v:
Croatian Medical Journal
Volume 60
Issue 3
Croatian medical journal
Volume 60
Issue 3
Croatian medical journal
We present the case of a 33-year-old chronic myeloid leukemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1687d79a758b3203b9c8040443a622cd
https://hrcak.srce.hr/240036
https://hrcak.srce.hr/240036
Autor:
Samia Menif, Amel Lakhal, Yosra Ben Youssef, Raihane Ben Lakhal, Manel Bedoui, Z. Manai, Mohamed Adnène Laatiri, Tarek Ben Othmen, Hela Ghedira, Neila Ben Romdhane, Abderrahmane Khélif, Hatem Bellaaj, F. Msadek, Balkis Meddeb, Moez Elloumi
Publikováno v:
Annals of Hematology
Annals of Hematology, Springer Verlag, 2018, 97 (4), pp.597--604. ⟨10.1007/s00277-017-3224-2⟩
Annals of Hematology, Springer Verlag, 2018, 97 (4), pp.597--604. ⟨10.1007/s00277-017-3224-2⟩
International audience; Data are limited in developing countries regarding the clinicopathologic features and response to therapy of chronic myeloid leukemia (CML) in the era of imatinib (IM). The objective of this study is to report on the clinicoep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66925fcc39af00c0fb63c3b0c040da14
https://hal.archives-ouvertes.fr/hal-01876259
https://hal.archives-ouvertes.fr/hal-01876259
Publikováno v:
Revista Brasileira de Cancerologia; Vol. 55 No. 4 (2009): Oct./Nov./Dec.; 375-378
Revista Brasileira de Cancerologia; Vol. 55 Núm. 4 (2009): oct./nov./dic.; 375-378
Revista Brasileira de Cancerologia; v. 55 n. 4 (2009): out./nov./dez; 375-378
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Revista Brasileira de Cancerologia; Vol. 55 Núm. 4 (2009): oct./nov./dic.; 375-378
Revista Brasileira de Cancerologia; v. 55 n. 4 (2009): out./nov./dez; 375-378
Revista Brasileira de Cancerologia
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
Este texto tem como objetivo apresentar ferramentas facilitadoras para implantar o segmento de acompanhamento farmacoterapêutico aos pacientes portadores de LMC, BCR-ABL positivos, em qualquer fase da doença e em uso do mesilato de imatinibe, busca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3056::7b2464c96a89586cd675085802471f6f
https://rbc.inca.gov.br/index.php/revista/article/view/1593
https://rbc.inca.gov.br/index.php/revista/article/view/1593